BIIB vs TSSI · P/E 21, rev $9.89B vs P/E 25, rev $148.1M
Biogen Inc (BIIB) versus TSS, Inc. Common Stock (TSSI) — a side-by-side from cached financials, not a winner call.
Biogen Inc (BIIB) is a drug manufacturers - general company listed on NASDAQ. It is led by Christopher A. Viehbacher.
TSS, Inc. Common Stock (TSSI) is a information technology services company listed on NASDAQ.
Latest reported BIIB revenue for 2025-12-31 was $9.89B. Net income was $1.29B. Revenue was up 2.2% from 2024-12-31 to 2025-12-31. BIIB currently screens at market cap $29.33B and trailing P/E 21.4.
Latest reported TSSI revenue for 2024-12-31 was $148.1M. Net income was $6.0M. Revenue was up 172.3% from 2023-12-31 to 2024-12-31. TSSI currently screens at market cap $360.8M and trailing P/E 24.7.
BIIB currently screens at market cap $29.33B and trailing P/E 21.4. TSSI currently screens at market cap $360.8M and trailing P/E 24.7.
Not investment advice. Open the BIIB and TSSI stock pages for the full models.
Not investment advice.